Page 17 - Dr Stephanie Seneff - Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID - 19

over relatively short timespans such as with MIS-C or could potentially not manifest for months or
years following exposure to the spike protein, whether via natural infection or via vaccination.

Many who test positive for COVID-19 express no symptoms. The number of asymptomatic, PCR-
positive cases varies widely between studies, from a low of 1.6% to a high of 56.5% (Gao et. al.,
2020). Those who are insensitive to COVID-19 probably have a very strong innate immune system.
The healthy mucosal barrier's neutrophils and macrophages rapidly clear the viruses, often without
the need for any antibodies to be produced by the adaptive system. However, the vaccine
intentionally completely bypasses the mucosal immune system, both through its injection past the
natural mucosal barriers and its artificial configuration as an RNA-containing nanoparticle. As noted
in Carsetti (2020), those with a strong innate immune response almost universally experience either
asymptomatic infection or only mild COVID-19 disease presentation. Nevertheless, they might face
chronic autoimmune disease, as described previously, as a consequence of excessive antibody
production in response to the vaccine, which was not necessary in the first place.

The Spleen, Platelets and Thrombocytopenia

Dr. Gregory Michael, an obstetrician in Miami Beach, died of a cerebral hemorrhage 16 days after
receiving the first dose of the Pfizer/BioNTech COVID-19 vaccine. Within three days of the
vaccine, he developed idiopathic thrombocytopenic purpura (ITP), an autoimmune disorder in
which the immune cells attack and destroy the platelets. His platelet count dropped precipitously,
and this caused an inability to stop internal bleeding, leading to the stroke, as described in an article
in the New York Times (Grady and Mazzei, 2021). The New York Times followed up with a second
article that discussed several other cases of ITP following SARS-CoV-2 vaccination (Grady, 2021),
and several other incidences of precipitous drop of platelets and thrombocytopenia following SARS-
CoV-2 vaccination have been reported in the Vaccine Adverse Event Reporting System (VAERS).

1. Biodistribution of mRNA Vaccines
Several studies on mRNA-based vaccines have confirmed independently that the spleen is a major
center of activity for the immune response. A study on an mRNA-based influenza virus vaccine is
extremely relevant for answering the question of the biodistribution of the mRNA in the vaccine.
This vaccine, like the SARS-CoV-2 vaccines, was designed as lipid nanoparticles with modified RNA
coding for hemagglutinin (the equivalent surface fusion protein to the spike protein in corona
viruses), and was administered through muscular injection. The concentration of mRNA was tracked
over time in various tissue samples, and the maximum concentration observed at each site was
recorded. Not surprisingly, the concentration was highest in the muscle at the injection site (5,680
ng/mL). This level decreased slowly over time, reaching half the original value at 18.8 hours
following injection. The next highest level was observed in the proximal lymph node, peaking at
2,120 ng/mL and not dropping to half this value until 25.4 hours later. Among organs, the highest
levels by far were found in the spleen (86.69 ng/mL) and liver (47.2 ng/mL). Elsewhere in the body
the concentration was at 100- to 1,000-fold lower levels. In particular, distal lymph nodes only had a
peak concentration of 8 ng/mL. They concluded that the mRNA distributes from the injection site
to the liver and spleen via the lymphatic system, ultimately reaching the general circulation. This
likely happens through its transport inside macrophages and other immune cells that take it up at the

International Journal of Vaccine Theory, Practice, and Research 2(1), May 10, 2021 Page | 405